Nilotinib for CML Leads to Fewer Treatment-Emergent Mutations Than Imatinib

CML patients treated with nilotinib had fewer treatment-emergent BCR-ABL mutations than those treated with imatinib, and among patients who did have a mutation, those treated with nilotinib had reduced rates of progression to accelerated phase and blast phase of the disease.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news

Related Links:

Date: Thursday, 04 09, 2020; Speaker: Zeynup Gumus, Assistant Professor, Ichan School of Medicine at Mount Sinai; https://cbiit.webex.com/mw3300/mywebex/default.do?
Source: NIH Calendar of Events - Category: American Health Source Type: events
Publication date: Available online 31 March 2020Source: CellAuthor(s): Marcus Ruscetti, John P. Morris, Riccardo Mezzadra, James Russell, Josef Leibold, Paul B. Romesser, Janelle Simon, Amanda Kulick, Yu-jui Ho, Myles Fennell, Jinyang Li, Robert J. Norgard, John E. Wilkinson, Direna Alonso-Curbelo, Ramya Sridharan, Daniel A. Heller, Elisa de Stanchina, Ben Z. Stanger, Charles J. Sherr, Scott W. Lowe
Source: Cell - Category: Cytology Source Type: research
Publication date: Available online 31 March 2020Source: Clinica Chimica ActaAuthor(s): Andras Komaromy, Balazs Reider, Gabor Jarvas, Andras Guttman
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Publication date: Available online 31 March 2020Source: Clinica Chimica ActaAuthor(s): Yueting Xiong, Chao Shi, Xiaohui Liu, Pengyuan Yang
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Authors: Ahmadianpour MV, Mowla J, Sotoodehnejadnematalahi F, Raheb J Abstract Studies on the blood of patients with prostate cancer using Dynamic Light Scattering (DLS) and corona protein size changes have shown that this test is highly specific and sensitive, but this method has not been studied in Iran, and therefore this study intends to perform this procedure using gold nanoparticles in prostate cancer detection. Blood samples of 60 male subjects aged 40-90 years were collected from 20 healthy, 20 benign and 20 prostate cancer patients. Optical scattering changes were measured by the level of gold nanoparticle...
Source: Human Antibodies - Category: Biochemistry Tags: Hum Antibodies Source Type: research
Conclusion: After the third relapse of HGSC, cytotoxic chemotherapy did not prolong survival but was associated with substantially increased healthcare costs. PMID: 32223298 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
CONCLUSION: Our results showed increased percentages of regulatory T cells in pediatric ALL patients despite chemotherapy, which might be compromising the anti-leukemic cellular immune response. PMID: 32224544 [PubMed - in process]
Source: Iranian Journal of Immunology - Category: Allergy & Immunology Tags: Iran J Immunol Source Type: research
CONCLUSION: These results suggested that rHP-NAP possesses the potential for use as an adjuvant of dendritic cell-based vaccine in anti-melanoma treatment. PMID: 32224538 [PubMed - in process]
Source: Iranian Journal of Immunology - Category: Allergy & Immunology Tags: Iran J Immunol Source Type: research
Publication date: Available online 31 March 2020Source: Life SciencesAuthor(s): Zhongqi Liu, Shi Cheng, Ganglan Fu, Fengtao Ji, Chengli Wang, Minghui Cao
Source: Life Sciences - Category: Biology Source Type: research
We present a case of a 79 year old patient with a medical history of unilateral nerve-sparing radical prostatectomy due to a pT3aN0 (Gleason score 7) prostate carcinoma. Because of slightly elevated prostate specific antigen (PSA) level (0.35ng/dL), a fluorine-18-prostate specific membrane antigen (18F-PSMA)-1007 positron emission tomography/computed tomography (PET/CT) scan was performed, showing no signs of malignant recurrence. However, a moderately PSMA-avid nodular lesion was observed in the left occipital region with homogeneous contrast enhancement, suggestive for a meningioma, which was confirmed on magnetic resona...
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
More News: Cancer | Cancer & Oncology | Gleevec | Nilotinib | Tasigna